

Stabilized α -helix-catalyzed enantioselective epoxidation of α,β -unsaturated ketones

Masanobu Nagano,^{†,n} Mitsunobu Doi,[¶] Masaaki Kurihara,[‡] Hiroshi Suemune,[†]

Masakazu Tanaka^{†,§,*}


[†]Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan; [‡]Division of Organic Chemistry, National Institute of Health Sciences, Tokyo 158-8501, Japan; [¶]Osaka University of Pharmaceutical Sciences, Osaka 569-1094, Japan; [§]Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan

matanaka@nagasaki-u.ac.jp

Supporting Information

Synthetic scheme of Boc-[L-Leu-L-Leu-dAA] _m -OMe (m = 1,2,3,4)	S2
Experimental Section	S3—S22
Fig. S1. CD spectra of Boc-[L-Leu-L-Leu-dAA] _m -OMe (m = 2,3,4)	S23
Table S1. Selected torsion angle ($^{\circ}$) for Boc-[L-Leu-L-Leu-(1 <i>S</i> ,3 <i>S</i>)-Ac ₅ c ^{OM}] _m -OMe 1e (m=2) and 2e (m=3), and H-[L-Leu- L-Leu-(<i>S,S</i>)-Ac ₅ c ^{dOM}] ₄ -OMe 6c determined by the X-ray crystallographic analysis	S24—S26
Fig. S2. Structures of Boc-protected Leu-heteropeptides 1e and 2e , and N-terminal free peptide 6c determined by the X-ray crystallographic analysis	S27
Table S2. Intra- and intermolecular H-bond parameters for	
Boc-[L-Leu-L-Leu-{(1 <i>S</i> ,3 <i>S</i>)-Ac ₅ c ^{OM} }] ₂ -OMe 1e	S28
Table S3. Intra- and intermolecular H-bond parameters for	
Boc-[L-Leu-L-Leu-{(1 <i>S</i> ,3 <i>S</i>)-Ac ₅ c ^{OM} }] ₃ -OMe 2e	S29
Table S4. Intra- and intermolecular H-bond parameters for	
H-[L-Leu-L-Leu-{(<i>S,S</i>)-Ac ₅ c ^{dOM} }] ₄ -OMe 6c	S30
Chart of ¹ H NMR spectra	S31—S70

Synthesis of oligopeptides: Boc or H-[L-Leu-L-Leu-dAA]_m-OMe.



Experimental Section


General. Optical rotations $[\alpha]_D$ were measured with a *Jasco DIP-316* polarimeter using a 0.5 or 1.0 dm cell. Circular dichroism spectra (CD) were measured with a *Jasco J-720W* spectropolarimeter using 1.0 mm path length cell. Infrared spectra (IR) were recorded on a *Jasco FT/IR-420* spectrometer for conventional measurement (KBr), and the solution (CDCl_3) method using 0.1 mm path length of NaCl cell. ^1H NMR spectra were determined at 400 or 500 MHz (*Varian Unity*). FAB-MS spectra were taken on a *Jeol JMS-SX 102* spectrometer. Chromatographic enantiomeric excess (ee) determinations were performed on *Jasco* HPLC instrument (Chiralcel OD column, Chiralpack AD column). Amino acids (*R,R*)- $\text{Ac}_5\text{c}^{\text{dOM}}$ (**b**) and (*S,S*)- $\text{Ac}_5\text{c}^{\text{dOM}}$ (**c**) were prepared from L- or D-dimethyl tartrate,^{S1} and amino acids (*1R,3S*)- $\text{Ac}_5\text{c}^{\text{OM}}$ (**d**) and (*1S,3S*)- $\text{Ac}_5\text{c}^{\text{OM}}$ (**e**) were prepared from L-(—)-malic acid.^{S2}

General procedure for peptide-catalyzed asymmetric epoxidation of chalcone. THF (1 mL) was added to the mixture of peptide catalyst (0.25 equiv) and chalcone (1.0 equiv) in a screw vial equipped with a magnetic stirring bar. Urea-hydrogenperoxide (1.1 equiv) and DBU (5.6 equiv) were added at 0 °C, and the mixture was gradually warmed to room temperature. After being stirred for 24 h, the reaction mixture was diluted with EtOAc, and washed with saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$. Then, organic layer was evaporated to give an oily residue, which was purified by flash column chromatography on silica gel.

General procedure for the preparation of α,β -unsaturated enones (7a–e, g, h).^{S3} 1N aqueous NaOH or KOH solution (2.6 mL) was added to the stirred solution of ketone derivative (1.1 equiv), aldehyde (1.0 equiv) in MeOH (8 mL) at °C. After being stirred at room temperature for 24 h, the solution was neutralized with 2N aqueous HCl, extracted with EtOAc, and dried over MgSO_4 . After removal of the solvent, the residue was purified by flash column chromatography on silica gel (EtOAc/hexane) to give enones in 20–76 % yields.

Enone (7f).^{S4} *trans*-1-Phenylbut-2-en-1-ol (3.37 mmol) was prepared from PhMgBr and *trans*-crotonaldehyde. Oxidation of the alcohol with MnO₂ (10 equiv) gave the ketone (53 %) as an orange oil. The spectroscopic data of **7f** were identical with those of reported compound.^{S4}

Boc-L-Leu-L-Leu-Aib-OMe (Aib-trimer; **9a**).^{S5} 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC; 671 mg, 3.50 mmol), and 1-hydroxybenzotriazole hydrate (HOEt; 567 mg, 4.20 mmol) were added to a stirred solution of carboxylic acid **Boc-L-Leu-L-Leu-OH** (1.20 g, 3.50 mmol) in CH₂Cl₂ (18 mL) at 0 °C, and the solution was stirred for 30 min. Then, a solution of amine **H-Aib-OMe** (410 mg, 3.50 mmol) in CH₂Cl₂ (8 mL) was added. After being stirred at room temperature for 48 h, the solution was diluted with EtOAc, washed with 3% aqueous HCl, 5% aqueous NaHCO₃, brine, and dried over MgSO₄. Removal of the solvent afforded a white solid, which was purified by column chromatography on silica gel. The fraction eluted with 50% EtOAc in hexane afforded trimer **9a** (907 mg, 82%) as colorless crystals: mp 149–151 °C; [α]²⁸_D = -68.4 (*c* 1.00, CHCl₃); IR (CDCl₃) 3434 (br), 2960, 1734, 1683, 1506, 1159 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.73 (br s, 1H), 6.41 (br d, *J* = 8.4 Hz, 1H), 4.81 (br s, 1H), 4.39 (m, 1H), 4.06 (m, 1H), 3.71 (s, 3H), 1.48–1.73 (m, 12H), 1.45 (s, 9H), 0.79–0.96 (m, 12H); HR-ESI(+)MS calcd for C₂₂H₄₁N₃O₆Na (M⁺+Na) 466.2888, found 466.2904.


Boc-L-Leu-L-Leu- $\{(R,R)\text{-Ac}_5\text{c}^{\text{dOM}}\}$ -OMe { (R,R) -trimer; **9b**}.⁵⁵ 

(R,R) -Trimer **9b** was prepared from **H-(R,R)-Ac₅c^{dOM}-OMe** and **Boc-L-Leu-L-Leu-OH** in a manner similar to that described for the preparation of **9a**: 82% yield; colorless crystals; mp 105–107 °C; $[\alpha]^{23}_{\text{D}} = -88.3$ (c 1.02, CHCl₃); IR (CDCl₃) 3431, 2960, 1742, 1698, 1683, 1507, 1456, 1369, 1237, 1162 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.88 (br s, 1H), 6.47 (br d, J = 8.0 Hz, 1H), 4.80 (br s, 1H), 4.38 (m, 1H), 4.07 (m, 1H), 3.77–3.86 (m, 2H), 3.69 (s, 3H), 3.34 (s, 3H), 3.33 (s, 3H), 2.47 (dd, J = 8.4, 15.2 Hz, 1H), 2.40 (dd, J = 6.4, 14.4 Hz, 1H), 2.33 (dd, J = 6.8, 14.4 Hz, 1H), 2.00 (dd, J = 3.2, 13.6 Hz, 1H), 1.48–1.71 (m, 6H), 1.44 (s, 9H), 0.90–0.96 (m, 12H); HR-ESI(+)MS calcd for C₂₆H₄₇N₃O₈Na (M⁺+Na) 552.3255,

found 552.3240.


Boc-L-Leu-L-Leu- $\{(S,S)\text{-Ac}_5\text{c}^{\text{dOM}}\}$ -OMe $\{(S,S)\text{-trimer}\}; \quad \mathbf{9c}\}$.^{S5}

(*S,S*)-Trimer **9c** was prepared from **H-(S,S)-Ac₅c^{dOM}-OMe** and **Boc-L-Leu-L-Leu-OH** in a manner similar to that described for the preparation of **9a**: 85% yield; colorless crystals; mp 72–74 °C; $[\alpha]^{25}_{\text{D}} = -31.2$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3432, 2983, 1743, 1683, 1506, 1455, 1436, 1369, 1162, 1105 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.86 (br s, 1H), 6.40 (br d, *J* = 8.0 Hz, 1H), 4.80 (br s, 1H), 4.38 (m, 1H), 4.07 (m, 1H), 3.88 (m, 1H), 3.81 (m, 1H), 3.70 (s, 3H), 3.36 (s, 3H), 3.34 (s, 3H), 2.50 (dd, *J* = 6.4, 14.8 Hz, 1H), 2.43 (dd, *J* = 7.2, 14.2 Hz, 1H), 2.27 (dd, *J* = 6.8, 14.2 Hz, 1H), 1.99 (dd, *J* = 3.2, 13.6 Hz, 1H), 1.46–1.71 (m, 6H), 1.45 (s, 9H), 0.90–0.96 (m, 12H); HR-ESI(+)MS calcd for C₂₆H₄₇N₃O₈Na (M⁺+Na) 552.3255, found 552.3229.




Boc-L-Leu-L-Leu- $\{(1R,3S)\text{-Ac}_5\text{c}^{\text{OM}}\}$ -OMe $\{(1R,3S)\text{-trimer}\}; \quad \mathbf{9d}\}$.

(1*R*,3*S*)-Trimer **9d** was prepared from **H-(1R,3S)-Ac₅c^{OM}-OMe** and **Boc-L-Leu-L-Leu-OH** in a manner similar to that described for the preparation of **9a**: 82% yield; colorless crystals; mp 109–111 °C; $[\alpha]^{27}_{\text{D}} = -81.8$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3421, 2960, 1698, 1683, 1540, 1522, 1507, 1497, 1165, 1067 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.90 (br s, 1H), 6.51 (br d, *J* = 6.6 Hz, 1H), 4.90 (br s, 1H), 4.40 (m, 1H), 4.08 (m, 1H), 3.93 (m, 1H), 3.68 (s, 3H), 3.26 (s, 3H), 2.25–2.35 (m, 2H), 1.45–2.14 (m, 10H), 1.44 (s, 9H), 0.90–0.95 (m, 12H); FAB(+)MS *m/z* 523 (M⁺+Na); HR-ESI(+)MS calcd for C₂₅H₄₅N₃O₇Na (M⁺+Na) 522.3150, found 522.3124.




Boc-L-Leu-L-Leu- $\{(1S,3S)\text{-Ac}_5\text{c}^{\text{OM}}\}$ -OMe $\{(1S,3S)\text{-trimer}\}; \quad \mathbf{9e}\}$.

(1*S*,3*S*)-Trimer **9e** was prepared from **H-(1S,3S)-Ac₅c^{OM}-OMe** and **Boc-L-Leu-L-Leu-OH** in a manner similar to that described for the preparation of **9a**: 84% yield; colorless crystals; mp 137–139 °C; $[\alpha]^{27}_{\text{D}} = -76.6$ (*c* 1.00, CHCl₃);




IR (CDCl₃) 3433, 3363, 2961, 2935, 2872, 1736, 1684, 1498, 1369, 1163, 1100 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.97 (br s, 1H), 6.48 (br d, *J* = 6.9 Hz, 1H), 4.92 (br s, 1H), 4.38 (m, 1H), 3.97—4.08 (m, 2H), 3.70 (s, 3H), 3.29 (s, 3H), 2.24—2.38 (m, 3H), 1.46—2.06 (m, 9H), 1.45 (s, 9H), 0.89—0.96 (m, 12H); FAB(+)MS *m/z* 523 (M⁺+Na); HR-ESI(+)MS calcd for C₂₅H₄₅N₃O₇Na (M⁺+Na) 522.3150, found 522.3131.


Boc-L-Leu-L-Leu-Aib-OH {Aib-trimer acid; 9a-CO₂H}.^{5S} 1N aqueous NaOH (9 mL) was added to a stirred solution of **9a** (2.00 g, 4.509 mmol) in MeOH (40 mL) at 0°C. After being stirred at room temperature for 12 h, the solution was acidified with 1N aqueous HCl, and then, MeOH was evaporated. The aqueous phase was extracted with EtOAc, and dried over Na₂SO₄. Removal of the solvent afforded a white solid, which was purified by column chromatography on silica gel. The fraction eluted with 10% MeOH in CHCl₃ gave Aib-trimer acid **9a-CO₂H** (1.80 g, 93%) as colorless crystals: mp 92—95 °C; [α]²⁶_D = - 58.4 (*c* 1.01, CHCl₃); IR (KBr) 3309 (br), 3072, 2958, 2872, 1691, 1654, 1527, 1170 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.08 (br s, 1H), 6.96 (br d, *J* = 8.0 Hz, 1H), 4.99 (br s, 1H), 4.52 (m, 1H), 4.12 (m, 1H), 1.48—1.70 (m, 12H), 1.44 (s, 9H), 0.90—0.95 (m, 12H); HR-ESI(+)MS calcd for C₂₁H₃₉N₃O₆Na (M⁺+Na) 452.2731, found 452.2750.



Boc-L-Leu-L-Leu-{(R,R)-Ac₅c^{dOM2H}.}^{5S} (R,R)-Trimer acid **9b-CO₂H** was prepared from **9b** in a manner similar to that described for the preparation of **9a-CO₂H**: 88% yield; colorless crystals; mp 81—83°C; [α]²⁸_D = - 75.0 (*c* 1.00, CHCl₃); IR (CDCl₃) 3316, 3072, 2958, 2935, 2872, 1693, 1652, 1526, 1367 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.18 (br s, 1H), 6.91 (br s, 1H), 5.00 (br s, 1H), 4.40 (m, 1H), 4.12 (m, 1H), 3.81—3.86 (m, 2H), 3.36 (s, 3H), 3.35 (s, 3H), 2.50—2.56 (m, 2H), 2.36 (dd, *J* = 6.0, 14.8 Hz, 1H), 2.06 (m, 1H), 1.50—1.66 (m, 6H), 1.44 (s, 9H), 0.89—0.95 (m, 12H); HR-ESI(+)MS calcd for C₂₅H₄₅N₃O₈Na (M⁺+Na) 538.3099, found 538.3110.



Boc-L-Leu-L-Leu-{(S,S)-Ac₅c^{dOM2H}.}^{5S}




(*S,S*)-Trimer acid **9c-CO2H** was prepared from **9c** in a manner similar to that described for the preparation of **9a-CO2H**: quantitative; colorless crystals; mp 76—77 °C; $[\alpha]^{25}_D = -30.0$ (*c* 1.01, CHCl₃); IR (KBr) 3317 (br), 3071, 2958, 2935, 1693, 1651, 1526, 1367, 1170, 1118 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.12 (br s, 1H), 6.93 (br s, 1H), 5.00 (br s, 1H), 4.42 (m, 1H), 4.10 (m, 1H), 3.89 (m, 1H), 3.83 (m, 1H), 3.36 (s, 3H), 3.35 (s, 3H), 2.60 (dd, *J* = 6.4, 14.4 Hz, 1H), 2.44 (dd, *J* = 7.2, 14.0 Hz, 1H), 2.28 (dd, *J* = 6.0, 14.0 Hz, 1H), 2.07 (dd, *J* = 3.2, 14.4 Hz, 1H), 1.45—1.66 (m, 6H), 1.44 (s, 9H), 0.90—0.95 (m, 12H); HR-ESI(+)MS calcd for C₂₅H₄₅N₃O₈Na (M⁺+Na) 538.3099, found 538.3101.


Boc-L-Leu-L-Leu-{(1*R*,3*S*)-Ac₅c^{OM}}-OH {(*1R,3S*)-trimer acid; **9d-CO2H}.** (*1R,3S*)-Trimer acid **9d-CO2H** was prepared from **9d** in a manner similar to that described for the preparation of **9a-CO2H**: 89% yield; colorless crystals; mp 85—88 °C; $[\alpha]^{26}_D = -61.9$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3308, 2958, 2872, 1695, 1651, 1526, 1367, 1170 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.17 (br s, 1H), 6.83 (br d, *J* = 8.8 Hz, 1H), 4.95 (br s, 1H), 4.40 (m, 1H), 4.11 (m, 1H), 3.95 (m, 1H), 3.27 (s, 3H), 2.44 (dd, *J* = 6.0, 14.4 Hz, 1H), 2.20—2.31 (m, 2H), 2.00—2.10 (m, 3H), 1.87 (m, 1H), 1.50—1.70 (m, 5H), 1.44 (s, 9H), 0.90—0.95 (m, 12H); FAB(+)MS *m/z* 509 (M⁺+Na); HR-ESI(+)MS calcd for C₂₄H₄₃N₃O₇Na (M⁺+Na): 508.2993, found 508.3005.

Boc-L-Leu-L-Leu-{(1*S,3S*)-Ac₅c^{OM}}-OH {(*1S,3S*)-trimer acid; **9e-CO2H}.** (*1S,3S*)-Trimer acid **9e-CO2H** was prepared from **9e** in a manner similar to that described for the preparation of **9a-CO2H**: quantitative; colorless crystals; mp 91—94 °C; $[\alpha]^{20}_D = -52.2$ (*c* 1.02, CHCl₃); IR (CDCl₃) 3317, 3072, 2959, 2935, 2872, 1692, 1649, 1527, 1367, 1170, 1105 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.35 (br s, 1H), 6.52 (br d, *J* = 6.8 Hz, 1H), 4.83 (br s, 1H), 4.41 (m, 1H), 4.14 (m, 1H), 4.06 (m, 1H), 3.40 (s, 3H), 2.63 (dd, *J* = 4.4, 14.8 Hz, 1H), 2.08—2.36 (m, 5H), 1.48—1.73 (m, 6H), 1.44 (s, 9H), 0.91—0.96 (m, 12H); FAB(+)MS *m/z* 509 (M⁺+Na); HR-ESI(+)MS calcd for C₂₄H₄₃N₃O₇Na (M⁺+Na) 508.2993, found 508.2990.

Boc-[L-Leu-L-Leu-Aib]₂-OMe {Aib-hexamer; 1a}. Concentrated HCl (3.6 mL) was added to a solution of **9a** (1.14 g, 2.57 mmol) in THF (10 mL) at 0 °C, and the whole was stirred at room temperature for 12 h. Then, the solution was neutralized with 5% aqueous NaHCO₃, extracted with EtOAc, and dried over MgSO₄. Removal of the solvent afforded a crude amine **9a-NH2** (686 mg, 78%), which was used without further purification. A mixture of EDC (421 mg, 2.20 mmol), HOBr (297 mg, 2.20 mmol), and carboxylic acid **9a-CO2H** (944 mg, 2.20 mmol) in CH₂Cl₂ (13 mL) was stirred at 0 °C for 30 min, then, a solution of amine **9a-NH2** (686 mg, 2.00 mmol) in CH₂Cl₂ (8 mL) was added. After being stirred at room temperature for 48 h, the solution was diluted with EtOAc, washed with 3% aqueous HCl, 5% aqueous NaHCO₃, brine, and dried over MgSO₄. After removal of the solvent, the residue was purified by column chromatography on silica gel (66% EtOAc in hexane) to give Aib-hexamer **1a** (1.43 g, 95%) as colorless crystals: mp 196—198 °C; [α]²⁷_D = - 22.8 (c 1.01, CHCl₃); IR (CDCl₃) 3430 (br), 3332, 3019, 2965, 1733, 1699, 1669, 1524, 1428, 1046 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.42 (br d, *J* = 6.8 Hz, 1H), 7.38 (br s, 1H), 6.20 (br d, *J* = 4.2 Hz, 1H), 7.11 (br s, 1H), 6.48 (br s, 1H), 4.95 (br s, 1H), 4.39 (m, 1H), 4.18 (m, 1H), 3.91—3.97 (m, 2H), 3.68 (s, 3H), 1.42—1.82 (m, 24H), 1.50 (s, 9H), 0.86—1.00 (m, 24H); FAB(+)MS *m/z* 778 (M⁺+Na); HR-ESI(+)MS calcd for C₃₈H₇₀N₆O₉Na (M⁺+Na) 777.5096, found 777.5132.




Boc-[L-Leu-L-Leu-{(R,R)-Ac₅c^{dOM}}]₂-OMe {(R,R)-hexamer; 1b}. (R,R)-Hexamer **1b** was prepared from **9b-NH2** and **9b-CO2H** in a manner similar to that described for the preparation of **1a**: 68% yield; colorless crystals; mp 167—169 °C; [α]²⁴_D = - 22.8 (c 1.00, CHCl₃); IR (CDCl₃) 3431, 3335, 2960, 1733, 1698, 1669, 1524, 1508, 1488, 1158, 1120 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.43 (br s, 1H), 7.31—7.32 (m, 2H), 7.26 (br s, 1H), 6.47 (br s, 1H), 4.96 (br s, 1H), 4.36 (m, 1H), 4.22 (m, 1H), 3.87—3.95 (m, 4H), 3.77—3.83 (m, 2H), 3.69 (s, 3H), 3.33—3.36 (m, 9H), 3.26 (s, 3H), 3.01 (dd, *J* = 5.6, 11.6 Hz, 1H), 2.88 (dd, *J* = 6.0, 11.6 Hz, 1H), 2.64 (dd, *J* = 6.0, 11.6 Hz, 1H), 2.53 (dd, *J* = 6.0, 11.6 Hz, 1H), 2.21 (dd, *J* = 6.0, 11.6 Hz, 1H), 2.07 (dd, *J* = 3.2, 13.2 Hz, 1H), 1.91—1.99 (m, 2H),



1.64—1.83 (m, 12H), 1.52 (s, 9H), 0.85—1.00 (m, 24H); FAB(+)MS m/z 950 (M^++Na); HR-ESI(+)MS calcd for $C_{46}H_{82}N_6O_{13}Na$ (M^++Na) 949.5832, found 949.5817.


Boc-[L-Leu-L-Leu- $\{(S,S)$ -Ac₅c^{OM}₂ $\}]_2$ -OMe { (S,S) -hexamer; **1c}.**

(S,S) -Hexamer **1c** was prepared from **9c-NH2** and **9c-CO2H** in a manner similar to that described for the preparation of **1a**: 68% yield; colorless crystals; mp 150—152 °C; $[\alpha]^{28}_D = +4.1$ (c 1.04, $CHCl_3$); IR ($CDCl_3$) 3333, 2959, 2901, 2826, 1741, 1670, 1522, 1508, 1159, 1051 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$) δ 7.23—7.35 (m, 4H), 6.70 (br s, 1H), 4.87 (br s, 1H), 4.35 (q, $J = 7.6$, 1H), 4.21 (m, 1H), 4.00 (m, 1H), 3.90—4.00 (m, 2H), 3.67—3.84 (m, 6H), 3.31—3.36 (m, 12H), 2.92 (dd, $J = 7.6$, 14.0 Hz, 1H), 2.65 (dd, $J = 8.0$, 14.0 Hz, 1H), 2.58 (dd, $J = 6.8$, 13.6 Hz, 1H), 2.42 (dd, $J = 6.4$, 13.6 Hz, 1H), 2.30 (dd, $J = 6.8$, 14.0 Hz, 1H), 2.13 (dd, $J = 7.2$, 14.0 Hz, 1H), 1.98 (dd, $J = 6.8$, 14.0 Hz, 1H), 1.91 (m, 1H), 1.60—1.80 (m, 12H), 1.49 (s, 9H), 0.85—1.00 (m, 24H); FAB(+)MS m/z 950 (M^++Na); HR-ESI(+)MS calcd for $C_{46}H_{82}N_6O_{13}Na$ (M^++Na) 949.5832, found 949.5806.




Boc-[L-Leu-L-Leu- $\{(1R,3S)$ -Ac₅c^{OM}₂ $\}]_2$ -OMe { $(1R,3S)$ -hexamer; **1d}.**

$(1R,3S)$ -Hexamer **1d** was prepared from **9d-NH2** and **9d-CO2H** in a manner similar to that described for the preparation of **1a**: 67% yield; colorless crystals; mp 184—186 °C; $[\alpha]^{27}_D = -1.5$ (c 1.01, $CHCl_3$); IR ($CDCl_3$) 3431, 3335, 2960, 1732, 1716, 1698, 1669, 1540, 1522, 1456, 1159 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 7.41 (br s, 1H), 7.34 (br s, 2H), 7.30 (br d, $J = 6.0$ Hz, 1H), 6.47 (br d, $J = 3.9$ Hz, 1H), 4.92 (br s, 1H), 4.39 (q, $J = 8.2$ Hz, 1H), 4.20 (q, $J = 6.4$ Hz, 1H), 3.89—3.96 (m, 4H), 3.68 (s, 3H), 3.26 (s, 3H), 3.18 (s, 3H), 2.84—2.89 (m, 2H), 1.63—2.33 (m, 22H), 1.50 (s, 9H), 0.86—1.00 (m, 24H); FAB(+)MS m/z 890 (M^++Na); HR-ESI(+)MS calcd for $C_{44}H_{78}N_6O_{11}Na$ (M^++Na) 889.5612, found 889.5653.




Boc-[L-Leu-L-Leu- $\{(1S,3S)$ -Ac₅c^{OM}₂ $\}]_2$ -OMe { $(1S,3S)$ -hexamer; **1e}.**

$(1S,3S)$ -Hexamer **1e** was prepared from **9e-NH2** and **9e-CO2H** in a manner similar to that described for the preparation of **1a**: 63% yield; colorless




crystals; mp 208–210 °C; $[\alpha]^{27}_D = -10.2$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3431 (br), 3332, 2961, 1698, 1667, 1526, 1468, 1369, 1256 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.49 (br s, 1H), 7.32 (br d, *J* = 5.5 Hz, 1H), 7.18 (br s, 1H), 6.55 (br s, 1H), 5.00 (d, *J* = 8.5 Hz, 1H), 4.33 (q, *J* = 8.0 Hz, 1H), 4.19 (m, 1H), 4.41–3.97 (m, 3H), 3.90 (m, 1H), 3.68 (s, 3H), 3.28 (s, 3H), 3.27 (s, 3H), 2.77 (m, 1H), 2.54 (dd, *J* = 6.6 Hz, 14.4 Hz, 1H), 2.45 (dd, *J* = 6.6 Hz, 14.4 Hz, 1H), 2.38 (dd, *J* = 5.3 Hz, 14.4 Hz, 1H), 2.25 (m, 1H), 2.11–2.17 (m, 2H), 1.99 (dd, *J* = 8.0 Hz, 14.2 Hz, 1H), 1.63–1.96 (m, 16H), 1.51 (s, 9H), 0.86–1.00 (m, 24H); FAB(+)MS *m/z* 890 (M⁺+Na); HR-ESI(+)MS calcd for C₄₄H₇₈N₆O₁₁Na (M⁺+Na) 889.5612, found 889.5621.

H-[L-Leu-L-Leu-Aib]₂-OMe {Aib-hexamer amine; 4a}. Concentrated HCl (2 mL) was added to a solution of **9a** (632 mg, 0.838 mmol) in THF (7 mL) at 0 °C and the solution was stirred at room temperature for 24 h. Then, the solution was neutralized with 5% aqueous NaHCO₃, extracted with EtOAc, and dried over MgSO₄. After removal of the solvent, the residue was purified by column chromatography on silica gel (10% MeOH in CHCl₃) to give Aib-hexamer amine **4a** (407 mg, 74%) as colorless crystals: mp 169–171 °C; $[\alpha]^{24}_D = -43.8$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3327 (br), 2960, 2872, 1733, 1669, 1540, 1522, 1508, 1157 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.95 (br s, 1H), 7.42 (br d, *J* = 8.2 Hz, 1H), 7.18 (br d, *J* = 6.4 Hz, 1H), 7.06 (br s, 1H), 6.55 (br s, 1H), 4.37 (m, 1H), 4.19 (m, 1H), 3.96 (m, 1H), 3.69 (s, 3H), 3.40 (dd, *J* = 3.6, 10.4 Hz, 1H), 1.56–1.82 (m, 12H), 1.52–1.53 (m, 6H), 1.48 (s, 3H), 1.42 (s, 3H), 0.86–1.01 (m, 24H); FAB(+)MS *m/z* 677 (M⁺+Na); HR-ESI(+)MS calcd for C₃₃H₆₂N₆O₇Na (M⁺+Na) 677.4572, found 677.4602.




H-[L-Leu-L-Leu-{(R,R)-Ac₅c^{dOM}}]₂-OMe {(R,R)-hexamer amine; 4b}. (R,R)-Hexamer amine **4b** was prepared from **1b** in a manner similar to that described for the preparation of **4a**: 70% yield; colorless crystals; mp 156–158 °C; $[\alpha]^{24}_D = -61.2$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3334 (br), 2960, 2935, 2873, 1734, 1668, 1523, 1467, 1105 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (br s, 1H), 7.24–7.22 (m, 2H), 7.19 (br d, *J* = 8.4 Hz, 1H), 6.80 (br s, 1H), 4.36 (m, 1H), 4.19 (m, 1H), 4.04 (m, 1H), 3.79–3.90 (m,



5H), 3.70 (s, 3H), 3.41 (dd, J = 3.6, 9.6 Hz, 1H), 3.35 (s, 6H), 3.33 (s, 3H), 3.31 (s, 3H), 2.68—2.78 (m, 2H), 2.58 (m, 1H), 2.27 (m, 1H), 2.16—2.22 (m, 2H), 2.04 (m, 1H), 1.96 (m, 1H), 1.60—1.81 (m, 12H), 0.87—0.99 (m, 24H); FAB(+)MS m/z 850 ($M^+ + \text{Na}$); HR-ESI(+)MS calcd for $\text{C}_{41}\text{H}_{74}\text{N}_6\text{O}_{11}\text{Na}$ ($M^+ + \text{Na}$) 849.5308, found 849.5275.

H-[L-Leu-L-Leu- $\{(S,S)\text{-Ac}_5\text{c}^{\text{DOM}}\}]_2\text{-OMe } \{(S,S)\text{-hexamer amine; 4c}\}.$


(*S,S*)-Hexamer amine **4c** was prepared from **1c** in a manner similar to that



described for the preparation of **4a**: 81% yield; colorless foam; $[\alpha]^{25}_D$ = + 3.6 (c 0.58, CHCl_3); IR (neat) 3311 (br), 2956, 2871, 1741, 1651, 1537, 1468, 1106 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.81 (br s, 1H), 7.35 (br d, J = 8.0 Hz, 1H), 7.26—7.30 (m, 2H), 6.94 (br s, 1H), 4.36 (m, 1H), 4.21 (m, 1H), 3.86—3.98 (m, 2H), 3.72—3.84 (m, 6H), 3.67 (s, 3H), 3.39 (s, 3H), 3.35 (s, 3H), 3.34 (s, 3H), 3.31 (s, 3H), 2.88 (m, 1H), 2.50—2.60 (m, 2H), 2.27 (m, 1H), 2.12 (m, 1H), 1.98 (m, 1H), 1.54—1.82 (m, 14H), 0.85—1.00 (m, 24H); FAB(+)MS m/z 850 ($M^+ + \text{Na}$); HR-ESI(+)MS calcd for $\text{C}_{41}\text{H}_{74}\text{N}_6\text{O}_{11}\text{Na}$ ($M^+ + \text{Na}$) 849.5308, found 849.5274.

H-[L-Leu-L-Leu- $\{(1R,3S)\text{-Ac}_5\text{c}^{\text{OM}}\}]_2\text{-OMe } \{(1R,3S)\text{-hexamer amine; 4d}\}.$


(*1R,3S*)-Hexamer amine **4d** was prepared from **1d** in a manner similar to that



described for the preparation of **4a**: 74% yield; colorless crystals; mp 158—160 °C; $[\alpha]^{24}_D$ = - 22.9 (c 1.00, CHCl_3); IR (CDCl_3) 3334 (br), 2960, 2872, 1732, 1669, 1521, 1508, 1456, 1216, 1098 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.88 (br d, J = 4.0 Hz, 1H), 7.30—7.32 (m, 2H), 7.23 (br s, 1H), 6.59 (br s, 1H), 4.39 (m, 1H), 4.19 (m, 1H), 3.92—3.99 (m, 3H), 3.68 (s, 3H), 3.39 (dd, J = 3.2, 13.2 Hz, 1H), 3.26 (s, 3H), 3.23 (s, 3H), 2.77 (dd, J = 6.4, 13.6 Hz, 1H), 2.69 (dd, J = 5.6, 14.8 Hz, 1H), 1.54—2.28 (m, 22H), 0.86—1.01 (m, 24H); FAB(+)MS m/z 768 ($M^+ + \text{H}$); HR-ESI(+)MS calcd for $\text{C}_{39}\text{H}_{70}\text{N}_6\text{O}_9\text{Na}$ ($M^+ + \text{Na}$) 789.5096, found 789.5117.

H-[L-Leu-L-Leu- $\{(1S,3S)\text{-Ac}_5\text{c}^{\text{OM}}\}]_2\text{-OMe } \{(1S,3S)\text{-hexamer amine; 4e}\}.$


(*1S,3S*)-Hexamer amine **4e** was prepared from **1e** in a manner similar to that



described for the preparation of **4a**: 93% yield; colorless crystals; mp


168—170 °C; $[\alpha]^{25}_D = -70.4$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3337 (br), 2960, 2872, 1733, 1668, 1521, 1508, 1217, 1099 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (br d, *J* = 6.0 Hz, 1H), 7.44 (br d, *J* = 6.0 Hz, 1H), 7.20 (br s, 1H), 7.14 (br d, *J* = 8.0 Hz, 1H), 7.01 (br s, 1H), 4.31 (m, 1H), 4.14—4.19 (m, 2H), 3.71—4.02 (m, 2H), 3.70 (s, 3H), 3.40 (dd, *J* = 4.0, 10.0 Hz, 1H), 3.30 (s, 3H), 3.28 (s, 3H), 2.35—2.50 (m, 3H), 2.04—2.21 (m, 4H), 1.58—1.91 (m, 16H), 0.88—0.97 (m, 24H); FAB(+)MS *m/z* 768 (M⁺+H); HR-ESI(+)MS calcd for C₃₉H₇₀N₆O₉Na (M⁺+Na) 789.5096, found 789.5113.

Boc-[L-Leu-L-Leu-Aib]₃-OMe {Aib-nonamer; 2a}. A solution of EDC (121 mg, 0.630 mmol), HOBr (85 mg, 0.630 mmol), carboxylic acid **9a-CO₂H** (270 mg, 0.630 mmol), and amine **4a** (344 mg, 0.525 mmol) in CH₂Cl₂ (14 mL) was stirred at room temperature for 48 h. Then, the solution was diluted with EtOAc, washed with 3% aqueous HCl, 5% aqueous NaHCO₃, brine, and dried over MgSO₄. After removal of the solvent, the residue was purified by column chromatography on silica gel (65% EtOAc in hexane) to give Aib-nonamer **2a** (343 mg, 61%) as colorless crystals: mp 215—217 °C; $[\alpha]^{28}_D = -22.5$ (*c* 1.03, CHCl₃); IR (CDCl₃) 3429, 3315, 3019, 2961, 2872, 1710, 1699, 1659, 1530, 1215 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.72 (br d, *J* = 4.0 Hz, 1H), 7.55 (br d, *J* = 6.0 Hz, 1H), 7.50 (br s, 1H), 7.41 (br s, 1H), 7.36 (br d, *J* = 4.0 Hz, 1H), 7.27 (br d, *J* = 4.8 Hz, 1H), 7.21 (br s, 1H), 6.58 (br s, 1H), 5.09 (br s, 1H), 4.39 (m, 1H), 4.17 (m, 1H), 3.91—4.03 (m, 4H), 3.68 (s, 3H), 1.47—1.91 (m, 45H), 0.86—1.01 (m, 36H); HR-ESI(+)MS calcd for C₅₄H₉₉N₉O₁₂Na (M⁺+Na) 1088.7305, found 1088.7307.



Boc-[L-Leu-L-Leu-{(R,R)-Ac_{5c}^{dOM}}₃-OMe {(R,R)-nonamer; 2b}.


(*R,R*)-Nonamer **2b** was prepared from **4b** and **9b-CO₂H** in a manner similar to that described for the preparation of **2a**: 90% yield; colorless crystals; mp 178—180 °C; $[\alpha]^{24}_D = -13.3$ (*c* 0.80, CHCl₃); IR (CDCl₃) 3430, 3316, 2826, 1698, 1655, 1532, 1158, 1121 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.67 (br d, *J* = 4.4 Hz, 1H), 7.63 (br s, 1H), 7.51 (br d, *J* = 4.0 Hz, 1H), 7.49 (br s, 1H), 7.44 (br s, 1H), 7.35 (br d, *J* = 4.8 Hz, 1H), 7.33 (br d, *J* = 6.4 Hz, 1H), 6.52 (br d, *J* = 2.4 Hz, 1H), 5.05 (br s, 1H), 4.35 (m, 1H), 4.20 (m, 1H), 3.89—4.04 (m, 7H),



3.76—3.83 (m, 3H), 3.69 (s, 3H), 3.31—3.39 (m, 15H), 3.25 (s, 3H), 3.18 (dd, J = 4.0, 12.0 Hz, 1H), 3.00 (dd, J = 5.2, 12.0 Hz, 1H), 2.91 (dd, J = 6.0, 11.2 Hz, 1H), 2.84 (dd, J = 5.2, 11.2 Hz, 1H), 2.66 (dd, J = 5.6, 11.6 Hz, 1H), 2.60 (dd, J = 6.0, 12.4 Hz, 1H), 2.15—2.23 (m, 2H), 1.45—2.00 (m, 22H), 1.52 (s, 9H), 0.85—1.00 (m, 36H); HR-ESI(+)MS calcd for $C_{66}H_{117}N_9O_{18}Na$ ($M^+ + Na$) 1346.8409, found 1346.8453.


Boc-[L-Leu-L-Leu- $\{(S,S)$ -Ac₅c^{DOM} $\}]_3$ -OMe {(S,S)-nonamer; 2c}.

(S,S)-Nonamer **2c** was prepared from **4c** and **9c-CO₂H** in a manner similar to that described for the preparation of **2a**: 85% yield; colorless crystals; mp 102—104 °C; $[\alpha]^{26}_D$ = + 22.8 (c 1.00, CHCl₃); IR (CDCl₃) 3325, 2959, 2901, 2826, 1661, 1525, 1508, 1159, 1106 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (br d, J = 5.2 Hz, 1H), 7.34—7.45 (m, 6H), 6.83 (br s, 1H), 5.02 (br s, 1H), 4.32 (m, 1H), 4.18 (m, 1H), 3.93—4.10 (m, 4H), 3.68—3.85 (m, 9H), 3.32—3.38 (m, 18H), 3.00 (dd, J = 4.0, 12.0 Hz, 1H), 2.65—2.80 (m, 3H), 1.47—2.40 (m, 26H), 1.50 (s, 9H), 0.85—1.02 (m, 36H); HR-ESI(+)MS calcd for $C_{66}H_{117}N_9O_{18}Na$ ($M^+ + Na$) 1346.8409, found 1346.8427.




Boc-[L-Leu-L-Leu- $\{(1R,3S)$ -Ac₅c^{OM} $\}]_3$ -OMe {(1R,3S)-nonamer; 2d}.

(1R,3S)-Nonamer **2d** was prepared from **4d** and **9d-CO₂H** in a manner similar to that described for the preparation of **2a**: 82% yield; colorless crystals; mp 228—230 °C; $[\alpha]^{27}_D$ = + 5.0 (c 1.00, CHCl₃); IR (CDCl₃) 3430, 3316, 2960, 2872, 1698, 1654, 1531, 1508, 1257, 1159 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.70 (br d, J = 4.7 Hz, 1H), 7.57 (br s, 1H), 7.53 (br s, 1H), 7.50 (br d, J = 5.6 Hz, 1H), 7.46 (br s, 1H), 7.42 (br d, J = 8.2 Hz, 1H), 7.36 (br d, J = 5.8 Hz, 1H), 6.52 (br d, J = 3.4 Hz, 1H), 5.00 (br s, 1H), 4.37 (m, 1H), 3.90—4.27 (m, 8H), 3.68 (s, 3H), 3.26 (s, 3H), 3.24 (s, 3H), 3.20 (s, 3H), 3.02 (dd, J = 6.7, 14.6 Hz, 1H), 2.89 (dd, J = 6.7, 13.9 Hz, 1H), 2.86 (dd, J = 6.2, 14.6 Hz, 1H), 2.15—2.47 (m, 4H), 1.56—2.06 (m, 29H), 1.51 (s, 9H), 0.85—1.01 (m, 36H); FAB(+)MS *m/z* 1257 ($M^+ + Na$); HR-ESI(+)MS calcd for $C_{63}H_{111}N_9O_{15}Na$ ($M^+ + Na$) 1256.8092, found 1256.8142.




Boc-[L-Leu-L-Leu- $\{(1S,3S)\text{-Ac}_5\text{c}^{\text{OM}}\}]_3\text{-OMe}$ {(1S,3S)-nonamer; 2e}.

(1S,3S)-Nonamer **2e** was prepared from **4e** and **9e-CO2H** in a manner similar to that described for the preparation of **2a**: 81% yield; colorless crystals; mp 234–236 °C; $[\alpha]^{27}_{\text{D}} = +5.6$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3429 (br), 3317, 2961, 2937, 2872, 1658, 1258, 1159 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.64 (br s, 1H), 7.59 (br d, *J* = 5.1 Hz, 1H), 7.56 (br s, 1H), 7.45 (br d, *J* = 5.1 Hz, 1H), 7.39 (br d, *J* = 7.7 Hz, 1H), 7.31 (br d, *J* = 6.2 Hz, 1H), 7.28 (br s, 1H), 6.58 (br s, 1H), 5.17 (br s, 1H), 3.90–4.33 (m, 9H), 3.68 (s, 3H), 3.29 (s, 3H), 3.28 (s, 3H), 3.27 (s, 3H), 2.74–2.89 (m, 3H), 2.51–2.59 (m, 2H), 2.37 (dd, *J* = 5.1 Hz, 14.1 Hz, 1H), 2.12–2.28 (m, 3H), 1.54–1.98 (m, 27H), 1.53 (s, 9H), 0.85–1.01 (m, 36H); FAB(+)MS *m/z* 1257 (M⁺+Na); HR-ESI(+)MS calcd for C₆₃H₁₁₁N₉O₁₅Na (M⁺+Na) 1256.8092, found 1256.8141.




H-[L-Leu-L-Leu-Aib]₃-OMe {Aib-nonamer amine; 5a}. Aib-nonamer amine **5a** was prepared from **2a** in a manner similar to that described for the preparation of **4a**: 81% yield; colorless crystals; mp 245–247 °C; $[\alpha]^{24}_{\text{D}} = -$

26.9 (*c* 1.00, CHCl₃); IR (CDCl₃) 3313 (br), 2960, 2871, 1733, 1656, 1531, 1468, 1157 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.73 (br d, *J* = 6.0 Hz, 1H), 7.55 (br d, *J* = 6.0 Hz, 1H), 7.48 (br d, *J* = 6.0 Hz, 1H), 7.38 (br s, 1H), 7.21–7.26 (m, 3H), 6.55 (br s, 1H), 4.36 (m, 1H), 4.15 (m, 1H), 4.02 (m, 1H), 3.92 (m, 2H), 3.68 (s, 3H), 3.41 (m, 1H), 1.40–1.81 (m, 36H), 0.85–1.03 (m, 36H); FAB(+)MS *m/z* 989 (M⁺+Na); HR-ESI(+)MS calcd for C₄₉H₉₂N₉O₁₀ (M⁺+H) 966.6962, found 966.6960.



H-[L-Leu-L-Leu- $\{(R,R)\text{-Ac}_5\text{c}^{\text{DOM}}\}]_3\text{-OMe}$ {(R,R)-nonamer amine; 5b}.


(R,R)-Nonamer amine **5b** was prepared from **2b** in a manner similar to that described for the preparation of **4a**: 82% yield; colorless crystals; mp 232–235 °C; $[\alpha]^{24}_{\text{D}} = -25.1$ (*c* 1.00, CHCl₃); IR (KBr) 3316 (br), 2960, 2936, 2872, 1734, 1657, 1531, 1467, 1120 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.02 (br d, *J* = 6.0 Hz, 1H), 7.69 (br d, *J* = 6.0 Hz, 1H), 7.62 (br s, 1H), 7.51 (br d, *J* = 6.4 Hz, 1H), 7.40 (br s, 1H), 7.31–7.35 (m, 2H), 6.67 (br s,



1H), 4.34 (m, 1H), 4.18 (m, 1H), 3.76—3.94 (m, 9H), 3.70 (s, 3H), 3.43 (m, 1H), 3.31—3.36 (m, 18H), 3.18 (m, 1H), 2.65—2.94 (m, 4H), 2.14—2.24 (m, 4H), 1.56—2.00 (m, 21H), 0.85—1.02 (m, 36H); FAB(+)MS m/z 1247 (M^++Na); HR-ESI(+)MS calcd for $C_{61}H_{109}N_9O_{16}Na$ (M^++Na) 1246.7884, found 1246.7931.

H-[L-Leu-L-Leu- $\{(S,S)\text{-Ac}_5\text{c}^{\text{dOM}}\}]_3\text{-OMe}$ {(S,S)-nonamer amine; 5c}.


(S,S)-Nonamer amine **5c** was prepared from **2c** in a manner similar to that



described for the preparation of **4a**: 85% yield; colorless crystals; mp 64—66 °C; $[\alpha]^{26}_D = + 25.5$ (c 1.01, CHCl₃); IR (KBr) 3319 (br), 2957, 2871, 1742, 1655, 1535, 1467, 1106 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (br s, 1H), 7.72 (br d, $J = 4.8$ Hz, 1H), 7.48 (br d, $J = 4.4$ Hz, 1H), 7.26—7.38 (m, 4H), 7.13 (br s, 1H), 4.33 (m, 1H), 4.20 (m, 1H), 4.05 (m, 1H), 3.72—3.94 (m, 9H), 3.68 (s, 3H), 3.32—3.41 (m, 18H), 2.98 (m, 1H), 2.64—2.72 (m, 2H), 2.50 (m, 1H), 2.35 (dd, $J = 7.2, 14.0$ Hz, 1H), 1.58—2.27 (m, 15H), 0.85—1.05 (m, 36H); FAB(+)MS m/z 1247 (M^++Na); HR-ESI(+)MS calcd for $C_{61}H_{109}N_9O_{16}Na$ (M^++Na) 1246.7884, found 1246.7879.

H-[L-Leu-L-Leu- $\{(1R,3S)\text{-Ac}_5\text{c}^{\text{OM}}\}]_3\text{-OMe}$ {(1R,3S)-nonamer amine; 5d}.


(1R,3S)-Nonamer amine **5d** was prepared from **2d** in a manner similar to that described for the preparation of **4a**: 62% yield; colorless crystals; mp



240—242 °C; $[\alpha]^{24}_D = + 4.4$ (c 1.00, CHCl₃); IR (CDCl₃) 3421, 3316 (br), 2960, 2872, 1732, 1655, 1530, 1508, 1102 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.70 (br d, $J = 4.8$ Hz, 1H), 7.57 (br d, $J = 5.2$ Hz, 1H), 7.52 (br s, 1H), 7.45 (br s, 1H), 7.41 (br d, $J = 8.0$ Hz, 1H), 7.35 (br d, $J = 6.0$ Hz, 1H), 7.26 (br s, 1H), 6.46 (br s, 1H), 4.37 (m, 1H), 4.18 (m, 1H), 3.92—4.04 (m, 7H), 3.68 (s, 3H), 3.40 (m, 1H), 3.24—3.26 (s, 9H), 3.01 (dd, $J = 6.8, 14.8$ Hz, 1H), 2.89 (dd, $J = 6.8, 14.4$ Hz, 1H), 2.79 (dd, $J = 5.6, 14.4$ Hz, 1H), 2.24—2.45 (m, 2H), 1.57—2.12 (m, 30H), 0.85—1.03 (m, 36H); FAB(+)MS m/z 1135 (M^++H); HR-ESI(+)MS calcd for $C_{58}H_{103}N_9O_{13}Na$ (M^++Na) 1156.7568, found 1156.7613.

H-[L-Leu-L-Leu- $\{(1S,3S)\text{-Ac}_5\text{c}^{\text{OM}}\}]_3\text{-OMe}$ {(1S,3S)-nonamer amine; 5e}.



(1S,3S)-Nonamer amine **5e** was prepared from **2e** in a manner similar to that



described for the preparation of **4a**: 69% yield; colorless crystals; mp 241–243 °C; $[\alpha]^{25}_D = -6.1$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3316 (br), 2960, 2936, 1654, 1532, 1508, 1101 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.10 (br s, 1H), 7.60 (br d, *J* = 4.0 Hz, 1H), 7.53 (br s, 1H), 7.52 (br d, *J* = 5.2 Hz, 1H), 7.40 (br d, *J* = 7.2 Hz, 1H), 7.30 (br d, *J* = 6.4 Hz, 1H), 7.21 (br s, 1H), 6.89 (br s, 1H), 4.30 (m, 1H), 4.18 (m, 1H), 3.91–4.06 (m, 6H), 3.68 (s, 3H), 3.44 (m, 1H), 3.27–3.28 (m, 9H), 2.75–2.83 (m, 3H), 2.54 (dd, *J* = 6.8, 14.8 Hz, 1H), 2.35 (dd, *J* = 4.8 Hz, 14.4 Hz, 1H), 2.28 (dd, *J* = 7.6 Hz, 11.2 Hz, 1H), 1.57–2.17 (m, 29H), 0.85–1.02 (m, 36H); FAB(+)MS *m/z* 1135 (M⁺+H); HR-ESI(+)MS calcd for C₅₈H₁₀₃N₉O₁₃Na (M⁺+Na) 1156.7568, found 1156.7612.

Boc-[L-Leu-L-Leu-Aib]₄-OMe {Aib-dodecamer; 3a}. A solution of EDC (46 mg, 0.238 mmol), HOBr (32 mg, 0.238 mmol), and carboxylic acid **9a-CO₂H** (102 mg, 0.238 mmol) in CH₂Cl₂ (4 mL) was stirred at 0 °C for 30 min. Then, a solution of amine **5a** (115 mg, 0.119 mmol) in CH₂Cl₂ (6 mL) was added. After being stirred at room temperature for 48 h, the solution was diluted with EtOAc, washed with 3% aqueous HCl, 5% aqueous NaHCO₃, brine, and dried over MgSO₄. After removal of the solvent, the residue was purified by column chromatography on silica gel (65% EtOAc in hexane) to give Aib-dodecamer **3a** (129 mg, 79%) as colorless crystals: mp 250–252 °C; $[\alpha]^{28}_D = -23.1$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3310, 3019, 2962, 2871, 1698, 1654, 1428, 1215, 1046 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (br d, *J* = 5.0 Hz, 1H), 7.75 (br d, *J* = 5.0 Hz, 1H), 7.58 (br d, *J* = 8.2 Hz, 1H), 7.54 (br s, 1H), 7.48 (br s, 1H), 7.45 (br s, 1H), 7.26–7.38 (m, 4H), 6.62 (br s, 1H), 5.12 (br s, 1H), 3.90–4.38 (m, 6H), 3.68 (s, 3H), 1.63–2.00 (m, 24H), 1.57 (s, 9H), 1.48–1.54 (m, 24H), 0.86–1.02 (m, 48H); FAB(+)MS *m/z* 1400 (M⁺+Na); HR-ESI(+)MS calcd for C₇₀H₁₂₈N₁₂O₁₅Na (M⁺+Na) 1399.9514, found 1399.9518.


Boc-[L-Leu-L-Leu-{(R,R)-Ac₅c^{dOM}}]₄-OMe {(R,R)-dodecamer; 3b}. (R,R)-Dodecamer **3b** was prepared from **5b** and **9b-CO₂H** in a manner similar to that described for the preparation of **3a**: 82% yield (mixture of Me and Et esters); colorless crystals; mp 244–246 °C; $[\alpha]^{24}_D = -9.8$ (*c* 1.00, CHCl₃); IR (CDCl₃)



3312 (br), 3293, 2960, 2932, 2872, 1698, 1653, 1533, 1508, 1122 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.69—7.80 (m, 4H), 7.38—7.53 (m, 6H), 6.80 (br s, 1H), 5.00 (br s, 1H), 3.77—4.34 (m, 16H), 3.70 (s, 3H), 3.26—3.37 (m, 24H), 2.60—3.21 (m, 8H), 1.66—2.24 (m, 32H), 1.51 (s, 9H), 0.85—1.03 (m, 48H); FAB(+)MS *m/z* 1745 (M⁺+Na); HR-ESI(+)MS calcd for C₈₆H₁₅₂N₁₂O₂₃Na (M⁺+Na) 1744.0986, found 1744.0979.

Boc-[L-Leu-L-Leu-{(S,S)-Ac₅c^{dOM}}]₄-OMe {(S,S)-dodecamer; 3c}.


(S,S)-Dodacamer **3c** was prepared from **5c** and **9c-CO₂H** in a manner similar to that described for the preparation of **3a**: 69% yield; colorless crystals; mp



122—124 °C; [α]²⁶_D = + 31.0 (*c* 1.00, CHCl₃); IR (CDCl₃) 3325, 2959, 2826, 1654, 1531, 1508, 1215, 1158, 1106 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.72 (br s, 1H), 7.68 (d, *J* = 5.2 Hz, 1H), 7.57 (br s, 1H), 7.33—7.54 (m, 7H), 6.78 (br s, 1H), 5.30 (br s, 1H), 3.70—4.34 (m, 16H), 3.67 (s, 3H), 3.25—3.39 (m, 24H), 1.57—3.10 (m, 40H), 1.51 (s, 9H), 0.85—1.04 (m, 48H); FAB(+)MS *m/z* 1745 (M⁺+Na); HR-ESI(+)MS calcd for C₈₆H₁₅₂N₁₂O₂₃Na (M⁺+Na) 1744.0986, found 1744.0926.


Boc-[L-Leu-L-Leu-{(1R,3S)-Ac₅c^{OM}}]₄-OMe {(1R,3S)-dodecamer; 3d}.

(1R,3S)-Dodacamer **3d** was prepared from **5d** and **9d-CO₂H** in a manner similar to that described for the preparation of **3a**: 94% yield; colorless crystals; mp 271—273 °C; [α]²⁷_D = + 6.5 (*c* 1.00, CHCl₃); IR (CDCl₃) 3311, 2960, 2872, 2825, 1653, 1532, 1105 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (br d, *J* = 4.3 Hz, 1H), 7.74 (br d, *J* = 4.5 Hz, 1H), 7.66 (br s, 1H), 7.62 (br s, 1H), 7.53 (br s, 1H), 7.44—7.50 (m, 4H), 7.39 (br d, *J* = 5.6 Hz, 1H), 6.52 (br d, *J* = 3.9 Hz, 1H), 4.99 (br s, 1H), 4.37 (m, 1H), 4.18 (m, 1H), 3.88—4.06 (m, 10H), 3.68 (s, 3H), 3.26 (s, 3H), 3.25 (s, 3H), 3.24 (s, 3H), 3.20 (s, 3H), 2.80—3.08 (m, 4H), 1.54—2.50 (m, 44H), 1.52 (s, 9H), 0.86—1.02 (m, 48H); FAB(+)MS *m/z* 1625 (M⁺+Na); HR-ESI(+)MS calcd for C₈₂H₁₄₄N₁₂O₁₉Na (M⁺+Na) 1624.0563, found 1624.0559.



Boc-[L-Leu-L-Leu-{(1S,3S)-Ac₅c^{OM}}]₄-OMe {(1S,3S)-dodecamer; 3e}.


(1S,3S)-Dodacamer **3e** was prepared from **5e** and **9e-CO₂H** in a manner



similar to that described for the preparation of **3a**: 90% yield; colorless crystals; mp 250–253 °C; $[\alpha]^{27}_D = +9.6$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3428 (br), 3315, 2960, 2937, 2871, 1654, 1533, 1368, 1101 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (br s, 1H), 7.62–7.71 (m, 4H), 7.53 (br d, *J* = 7.3 Hz, 1H), 7.47 (br s, 1H), 7.29–7.33 (m, 3H), 7.08 (br s, 1H), 5.76 (br s, 1H), 4.28 (m, 1H), 4.19 (m, 1H), 3.90–4.17 (m, 10H), 3.67 (s, 3H), 3.25–3.28 (m, 12H), 1.61–2.90 (m, 48H), 1.53 (s, 9H), 0.85–1.02 (m, 48H); FAB(+)MS *m/z* 1625 (M⁺+Na); HR-ESI(+)MS calcd for C₈₂H₁₄₄N₁₂O₁₉Na (M⁺+Na) 1624.0563, found 1624.0547.


H-[L-Leu-L-Leu-Aib]₄-OMe {Aib-dodecamer amine; **6a}.**

Aib-dodecamer amine **6a** was prepared from **3a** in a manner similar to that described for the preparation of **4a**: 89% yield; colorless crystals; mp 249–251 °C; $[\alpha]^{24}_D = -30.5$ (*c* 1.01, CHCl₃); IR (CDCl₃) 3309 (br), 2960, 2871, 1732, 1654, 1533, 1468, 1386, 1365, 1288 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.21 (br s, 1H), 7.81–7.83 (m, 2H), 7.65 (br s, 1H), 7.50–7.52 (m, 3H), 7.30–7.32 (m, 3H), 7.03 (br s, 1H), 4.32 (m, 1H), 4.13 (m, 1H), 4.00–4.08 (m, 2H), 3.89–3.93 (m, 3H), 3.68 (s, 3H), 3.44 (m, 1H), 1.38–2.00 (m, 48H), 0.85–1.03 (m, 48H); FAB(+)MS *m/z* 1300 (M⁺+Na); HR-ESI(+)MS calcd for C₆₅H₁₂₀N₁₂O₁₃Na (M⁺+Na) 1299.8990, found 1299.8949.



H-[L-Leu-L-Leu-{(R,R)-Ac₅c^{dOM}}]₄-OMe {(R,R)-dodecamer amine; **6b}.**


(*R,R*)-Dodecamer amine **6b** was prepared from **3b** in a manner similar to that described for the preparation of **4b**: 73% yield (mixture of Me and Et esters); colorless crystals; mp 249–251 °C; $[\alpha]^{24}_D = -16.0$ (*c* 1.00, CHCl₃); IR (CDCl₃) 3312 (br), 2959, 2936, 2872, 1654, 1535, 1508, 1122 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.38 (br, 1H), 7.98 (br s, 1H), 7.85–7.88 (m, 3H), 7.76 (br s, 1H), 7.63 (br s, 1H), 7.57 (br s, 1H), 7.42 (br d, *J* = 3.2 Hz, 1H), 7.34–7.37 (m, 2H), 4.30 (m, 1H), 4.16 (m, 1H), 3.91–4.06 (m, 10H), 3.73–3.82 (m, 3H), 3.71 (s, 3H), 3.51 (m, 1H), 3.28–3.36 (m, 24H), 3.18 (dd, *J* = 8.0, 14.4 Hz, 1H), 3.08 (dd, *J* = 8.0, 15.2 Hz, 1H), 3.00 (dd, *J* = 6.8, 14.8 Hz, 1H), 2.83–2.90 (m, 2H), 2.64 (m, 1H), 2.39 (m, 1H), 1.65–2.24 (m, 32H), 1.03–0.86 (m, 48H); FAB(+)MS *m/z* 1645 (M⁺+Na); HR-ESI(+)MS calcd for



$C_{81}H_{122}N_{12}O_{21}$ ($M^+ + H$) 1622.0642, found 1622.0564.

H-[L-Leu-L-Leu- $\{(S,S)\text{-Ac}_5\text{c}^{\text{dOM}}\}]_4\text{-OMe }$ {(S,S)-dodecamer amine; 6c}.


(S,S)-Dodecamer amine **6c** was prepared from **3c** in a manner similar to that described for the preparation of **4c**: 67% yield; colorless crystals; mp



120—122 °C; $[\alpha]^{26}_D = + 31.7$ (c 1.00, $CHCl_3$); IR (KBr) 3316 (br), 2957, 2871, 2825, 1740, 1663, 1538, 1468, 1106 cm^{-1} ; ^1H NMR (400 MHz, $CDCl_3$) δ 8.15 (br s, 1H), 7.73—7.80 (m, 2H), 7.62 (br s, 1H), 7.30—7.53 (m, 4H), 7.28—7.29 (m, 2H), 7.27 (br d, $J = 4.4$ Hz, 1H), 4.33 (m, 2H), 3.69—4.19 (m, 38H), 3.67 (s, 3H), 3.32—3.42 (m, 24H), 3.03 (m, 2H), 2.65—2.77 (m, 6H), 2.53 (m, 1H), 1.62—2.41 (m, 31H), 0.85—1.06 (m, 48H); FAB(+)MS m/z 1645 ($M^+ + Na$); HR-ESI(+)MS calcd for $C_{81}H_{122}N_{12}O_{21}Na$ ($M^+ + Na$) 1644.0461, found 1644.0382.

H-[L-Leu-L-Leu- $\{(1R,3S)\text{-Ac}_5\text{c}^{\text{OM}}\}]_4\text{-OMe }$ {(1R,3S)-dodecamer amine; 6d}.


(1R,3S)-Dodecamer amine **6d** was prepared from **3d** in a manner similar to that described for the preparation of **4d**: 60% yield; colorless crystals; mp



262—265 °C; $[\alpha]^{24}_D = + 6.2$ (c 1.00, $CHCl_3$); IR ($CDCl_3$) 3311 (br), 2960, 2872, 2826, 1653, 1532, 1103 cm^{-1} ; ^1H NMR (400 MHz, $CDCl_3$) δ 8.08 (br s, 1H), 7.79 (br d, $J = 3.2$ Hz, 1H), 7.75 (br d, $J = 3.2$ Hz, 1H), 7.66 (br s, 1H), 7.58—7.59 (m, 2H), 7.52 (br s, 1H), 7.45—7.47 (m, 2H), 7.38 (br d, $J = 4.8$ Hz, 1H), 6.50 (br s, 1H), 4.36 (m, 1H), 4.11—4.16 (m, 2H), 3.94—4.02 (m, 5H), 3.68 (s, 3H), 3.41 (m, 1H), 3.24—3.26 (m, 12H), 2.78—3.05 (m, 4H), 1.57—2.50 (m, 44H), 0.87—1.04 (m, 48H); FAB(+)MS m/z 1525 ($M^+ + Na$); HR-ESI(+)MS calcd for $C_{77}H_{136}N_{12}O_{17}Na$ ($M^+ + Na$) 1524.0039, found 1524.0089.

H-[L-Leu-L-Leu- $\{(1S,3S)\text{-Ac}_5\text{c}^{\text{OM}}\}]_4\text{-OMe }$ {(1S,3S)-dodecamer amine; 6e}.

(1S,3S)-Dodecamer amine **6e** was prepared from **3e** in a manner similar to that described for the preparation of **4e**: 67% yield; colorless crystals; mp




243—245 °C; $[\alpha]^{25}_D = + 7.8$ (c 1.03, $CHCl_3$); IR ($CDCl_3$) 3310 (br), 2959, 2935, 2871, 1653, 1540, 1101 cm^{-1} ; ^1H NMR (400 MHz, $CDCl_3$) δ 8.60 (br, 1H), 7.80—8.04 (m, 8H), 7.38 (br s, 1H), 7.10 (br


s, 1H), 3.91—4.27 (m, 11H), 3.69 (s, 3H), 3.49 (m, 1H), 3.24—3.28 (m, 12H), 1.79—2.82 (m, 48H), 0.90—1.02 (m, 48H); FAB(+)MS m/z 1525 ($M^+ + \text{Na}$); HR-ESI(+)MS calcd for $C_{77}\text{H}_{136}\text{N}_{12}\text{O}_{17}\text{Na}$ ($M^+ + \text{Na}$) 1524.0039, found 1524.0087.

Following epoxides are known compounds. The spectroscopic data of these compounds are in accordance with those of reported ones. The absolute configurations of epoxides were determined by the comparison of the specific rotations with literature values.


(2*R*,3*S*)-*trans*-Epoxy-3-phenyl-1-phenylpropan-1-one (8a). Colorless crystals; $[\alpha]^{23}_D = -215.1$ (c 1.00, CHCl_3) [Lit.,⁶⁸ another (2*S*,3*R*)-enantiomer, $[\alpha]_D = +182.2$ (c 1.14, CHCl_3)]; ^1H NMR (400MHz, CDCl_3) δ 8.00—8.02 (m, 2H), 7.36—7.62 (m, 8H), 4.29 (d, $J = 1.6$ Hz, 1H), 4.08 (d, $J = 1.6$ Hz, 1H). HPLC (DAICEL Chiralpak AD column, 4.6 mmφ x 250 mm; 10% EtOH in hexane; flow rate, 1.0 mL/min): retention time (t_R) = 19.1 min (2*R*,3*S*-enantiomer, major), 26.4 min (2*S*,3*R*-enantiomer, minor).




(3*R*,4*S*)-*trans*-Epoxy-4-phenylbutan-2-one (8b). Colorless oil; $[\alpha]^{26}_D = -64.6$ (c 1.05, CHCl_3) [Lit.,⁷⁸ -73.3 (c 1.00, CHCl_3)]; ^1H NMR (400MHz, CDCl_3) δ 7.35—7.40 (m, 3H), 7.27—7.29 (m, 2H), 4.00 (d, $J = 1.6$ Hz, 1H), 3.49 (d, $J = 1.6$ Hz, 1H), 2.19 (s, 3H). HPLC (DAICEL Chiralpak AD column, 4.6 mmφ x 250 mm; 10% EtOH in hexane; flow rate, 1.0 mL/min): $t_R = 8.3$ min (2*R*,3*S*-enantiomer, major), 18.9 min (2*S*,3*R*-enantiomer, minor).




(4*R*,5*S*)-*trans*-Epoxy-2-methyl-5-phenylpentan-3-one (8c). Colorless crystals; $[\alpha]^{26}_D = -149.8$ (c 1.00, CHCl_3) [Lit.,⁸⁸ -208 (c 1.0, CHCl_3)]; ^1H NMR (400MHz, CDCl_3) δ 7.28—7.40 (m, 5H), 3.92 (d, $J = 2.0$ Hz, 1H), 3.60 (d, $J = 2.0$ Hz, 1H), 1.17 (q, $J = 5.2$, 6H). HPLC (DAICEL Chiralpak AD column, 4.6 mmφ x 250 mm; 5% EtOH in hexane; flow rate, 0.7 mL/min): $t_R = 14.5$ min (2*R*,3*S*-enantiomer, major), 25.4 min (2*S*,3*R*-enantiomer, minor).




(1S,2R)-trans-1,2-Epoxy-4,4-dimethyl-1-phenylpentan-3-one (8d). Colorless crystals; $[\alpha]^{26}_D = -158.1$ (*c* 1.00, CHCl₃) [Lit.,^{9S} -194 (*c* 1, CHCl₃)]; ¹H NMR (400MHz, CDCl₃) δ 7.30—7.39 (m, 5H), 3.86 (s, 2H), 1.24 (s, 9H). HPLC (DAICEL Chiralpak AD column, 4.6 mmφ x 250 mm; 5% EtOH in hexane; flow rate, 0.7 mL/min): *t*_R = 15.0 min (2*S*,3*R*-enantiomer, minor), 20.8 min (2*R*,3*S*-enantiomer, major).




(2R,3S)-trans-Epoxy-3-phenyl-1-(2-furyl)propan-1-one (8e). Colorless crystals; $[\alpha]^{26}_D = -190.0$ (*c* 1.00, CHCl₃) [Lit.,^{10S} -200 (*c* 1.0, CHCl₃)]; ¹H NMR (400MHz, CDCl₃) δ 7.67 (m, 1H), 7.46 (d, *J* = 4.0 Hz, 1H), 6.59—6.60 (m, 5H), 4.2 (m, 2H). HPLC (DAICEL Chiralcel OD column, 4.6 mmφ x 250 mm; 5% *i*PrOH in hexane; flow rate, 0.8 mL/min): *t*_R = 25.0 min (2*S*,3*R*-enantiomer, minor), 26.4 min (2*R*,3*S*-enantiomer, major).




(2R,3S)-trans-Epoxy-3-methyl-1-phenylpropan-1-one (8f). Colorless crystals; $[\alpha]^{26}_D = -5.5$ (*c* 1.00, CHCl₃) [Lit.,^{11S} -10.0 (*c* 0.6, CHCl₃)]; ¹H NMR (400MHz, CDCl₃) δ 8.01—8.26 (m, 2H), 7.61 (m, 1H), 7.48—7.52 (m, 1H), 3.97 (s, 1H), 3.23 (m, 1H), 1.52 (d, *J* = 4.4, 3H). HPLC (DAICEL Chiralcel OD column, 4.6 mmφ x 250 mm; 5% *i*PrOH in hexane; flow rate, 0.8 mL/min): *t*_R = 9.1 min (2*S*,3*S*-enantiomer, minor), 9.8 min (2*R*,3*S*-enantiomer, major).



(2R,3S)-trans-Epoxy-3-(4-chlorophenyl)-1-phenylpropan-1-one (8g). Thin yellow crystals; $[\alpha]^{26}_D = -214.4$ (*c* 1.00, CH₂Cl₂) [Lit.,^{10S} -233 (*c* 1.0, CH₂Cl₂)]; ¹H NMR (400MHz, CDCl₃) δ 7.99—8.01 (m, 2H), 7.61—7.65 (m, 2H), 7.48—7.52 (m, 2H), 7.38 (d, *J* = 8.4 Hz, 2H), 7.31 (d, *J* = 8.4 Hz, 2H), 4.24 (d, *J* = 1.6 Hz, 1H), 4.06 (d, *J* = 1.6 Hz, 1H). HPLC (DAICEL Chiralcel OD column, 4.6 mmφ x 250 mm; 2% *i*PrOH in hexane; flow rate, 0.6 mL/min): *t*_R = 39.9 min (2*S*,3*R*-enantiomer, minor), 43.2 min (2*R*,3*S*-enantiomer, major).



(2R,3S)-trans-Epoxy-3-(4-methoxyphenyl)-1-phenylpropan-1-one



(8h). Thin yellow crystals; $[\alpha]^{26}_D = -191.5$ (*c* 1.00, CHCl₃) [Lit.,^{12S} another 2*S*,3*R*-enantiomer, +131 (*c* 0.70, CHCl₃)]; ¹H NMR (400MHz, CDCl₃) δ 8.01 (d, *J* = 7.2 Hz, 2H), 7.62 (m, 1H), 7.47—7.52 (m, 2H), 7.30 (d, *J* = 8.8 Hz, 2H), 6.94—6.92 (m, 2H), 4.28 (d, *J* = 1.6 Hz, 1H), 4.03 (d, *J* = 1.6 Hz, 1H), 3.83 (s, 3H). HPLC (DAICEL Chiralcel OD column, 4.6 mmφ x 250 mm; 5% *i*PrOH in hexane; flow rate, 0.8 mL/min): *t*_R = 21.3 min (2*S*,3*R*-enantiomer, minor), 23.0 min (2*R*,3*S*-enantiomer, major).

References of Experimental Section.

- (S1) M. Tanaka, Y. Demizu, M. Doi, M. Kurihara, H. Suemune, *Angew. Chem. Int. Ed.*, **2004**, *43*, 5360—5363.
- (S2) M. Nagano, M. Tanaka, M. Doi, Y. Demizu, M. Kurihara, H. Suemune, *Org. Lett.*, **2009**, *11*, 1135—1137.
- (S3) M. Cabrera, M. Simoens, G. Falchi, M. L. Lavaggi, O. E. Piro, E. E. Castellano, A. Vidal, A. Azqueta, A. Monge, A. Lo'pez de Cera'in, G. Sagrera, G. Seoane, H. Cerecetto, M. Gonza'lez. *Bioorg. Med. Chem.* **2007**, *15*, 3356—3367.
- (S4) F. D. Therkelsen, A. L. Hansen, E. B. Pedersen and C. Nielsen. *Org. Biomol. Chem.*, **2003**, *1*, 2908—2918.
- (S5) Y. Demizu, M. Tanaka, M. Nagano, M. Kurihara, M. Doi and H. Suemune, *Chem. Pharm. Bull.*, **2007**, *55*, 840—842.
- (S6) M. Bougauchi, S. Watanabe, T. Arai, H. Sasaki, M. Shibasaki, *J. Am. Chem. Soc.*, **1997**, *119*, 2329—2330.
- (S7) B. M. Adger, J. V. Barkley, S. Bergeron, M. W. Cappi, B. E. Flowerdew, M. P. Jackson, R. MacCague, T. C. Nugent, S. M. Roberts, *J. Chem. Soc., Perkin Trans. I*, **1997**, 3501—3507.
- (S8) J. F. Bickley, S. M. Roberts, Y. Runhui, J. Skidmore, C. B. Smith, *Tetrahedron*, **2003**, *59*, 5731—5736.
- (S9) T. Nemoto, T. Ohshima, K. Yamaguchi, M. Shibasaki, *J. Am. Chem. Soc.*, **2001**, *123*, 2725—2726.
- (S10) B. M. Choudary, M. L. Kantam, K. V. S. Ranganath, K. Mahendar, B. Sreedhar, *J. Am. Chem. Soc.*, **2004**, *126*, 3396—3397.
- (S11) A. Lattanzi, *Org. Lett.*, **2005**, *7*, 2579—2582.
- (S12) B. Lygo, P. G. Wainwright, *Tetrahedron*, **1999**, *55*, 6289—6300.

Fig. S1. CD spectra of Boc-[L-Leu-L-Leu-dAA]_m-OMe ($m = 2,3,4$).





Table S2. Selected torsion angle ($^{\circ}$) for Boc-[L-Leu-L-Leu-(1*S*,3*S*)-Ac₅c^{OM}]_m-OMe **1e** ($m=2$) and **2e** ($m=3$), and H-[L-Leu-L-Leu-(*S,S*)-Ac₅c^{dOM}]₄-OMe **6c** determined by the X-ray crystallographic analysis.




Torsion Angle	Boc-[L-Leu-L-Leu-(1 <i>S</i> ,3 <i>S</i>)-Ac ₅ c ^{OM}] ₂ -OMe 1e	Molecule A	Molecule B	Molecule C	Boc-[L-Leu-L-Leu-(1 <i>S</i> ,3 <i>S</i>)-Ac ₅ c ^{OM}] ₃ -OMe 2e	Molecule A	Molecule B	H-[L-Leu-L-Leu-(<i>S,S</i>)-Ac ₅ c ^{dOM}] ₄ -OMe 6c
ω_0	171.8	176.0	178.4	178.4	168.3	−178.8	−	−
ϕ_1	−67.8	−68.3	−68.5	−68.5	−65.0	−80.1	−	−
ψ_1	−16.3	−15.0	−14.6	−14.6	−34.5	−43.2	−12.0	−
ω_1	173.2	171.7	172.4	172.4	−177.9	−179.2	−173.5	−
ϕ_2	−57.9	−55.3	−62.2	−62.2	−59.3	−56.2	−50.3	−
ψ_2	−30.0	−32.0	−24.5	−24.5	−50.0	−41.5	−44.8	−
ω_2	178.6	178.4	175.9	175.9	−177.8	−179.6	−176.4	−
ϕ_3	−60.9	−61.7	−56.1	−56.1	−54.3	−54.0	−57.7	−
ψ_3	−33.0	−30.5	−38.4	−38.4	−53.2	−47.4	−43.6	−
ω_3	179.2	175.1	178.5	178.5	−173.5	−178.6	−179.4	−
ϕ_4	−86.3	−86.6	−77.3	−77.3	−65.0	−62.7	−70.0	−
ψ_4	−36.8	−35.4	−39.8	−39.8	−44.2	−45.6	−40.8	−

ω_4	177.4	178.7	177.6	-177.9	-174.4	-179.1
ϕ_5	-65.1	-62.2	-62.9	-66.7	-70.0	-60.5
ψ_5	-42.3	-39.6	-40.8	-43.8	-34.7	-45.5
ω_5	174.1	179.8	175.9	178.9	176.7	-179.2
ϕ_6	-56.8	52.3	56.5	-55.1	-56.3	-58.1
ψ_6	-37.7	39.5	38.0	-43.1	-44.4	-50.9
ω_6	-165.5	177.3	175.0	-173.4	-179.6	-175.2
ϕ_7	-	-	-	-72.9	-72.3	-64.2
ψ_7	-	-	-	-45.3	-43.4	-45.4
ω_7	-	-	-	-169.9	-173.4	-177.0
ϕ_8	-	-	-	-85.3	-65.6	-61.6
ψ_8	-	-	-	-29.8	-48.5	-41.2
ω_8	-	-	-	-174.2	-179.2	-179.5
ϕ_9	-	-	-	51.7	51.7	-55.3
ψ_9	-	-	-	32.3	47.0	-41.9
ω_9	-	-	-	172.4	175.5	-176.3
ϕ_{10}	-	-	-	-	-	-78.2
ψ_{10}	-	-	-	-	-	-26.6
ω_{10}	-	-	-	-	-	176.8
ϕ_{11}	-	-	-	-	-	-78.5
ψ_{11}	-	-	-	-	-	-15.9
ω_{11}	-	-	-	-	-	174.5
ϕ_{12}	-	-	-	-	-	58.7
ψ_{12}	-	-	-	-	-	36.2
ϕ_{12}	-	-	-	-	-	179.7


χ_1	-85.8	-62.5	-61.1	-175.6	-178.5	-66.9
χ_2	-111.2	-176.7	-80.6	-172.4	-177.2	-179.1
χ_3	-86.3	-85.6	-97.7	-84.4	-93.7	-149.9
χ_3'	75.9	73.1	71.4	80.4	76.8	126.4
χ_4	-80.7	-71.1	-70.0	-70.0	-178.2	-61.1
χ_5	-178.9	-176.8	-173.4	-160.5	-58.0	-66.6
χ_6	-93.0	-84.5	-113.0	-81.0	-89.1	-148.5
χ_6'	62.6	79.6	92.0	84.8	97.3	118.7
χ_7	-	-	-	176.0	-72.1	179.0
χ_8	-	-	-	-86.4	-179.9	-176.5
χ_9	-	-	-	-84.0	-89.3	-143.0
χ_9'	-	-	-	76.9	111.8	116.1
χ_{10}	-	-	-	-	-	-65.0
χ_{11}	-	-	-	-	-	-66.2
χ_{12}	-	-	-	-	-	-124.8
χ_{12}'	-	-	-	-	-	99.7

Fig. S2. Structures of Boc-protected Leu-heteropeptides **1e** and **2e**, and N-terminal free peptide **6c** determined by the X-ray crystallographic analysis.

(a) Boc-[(Leu)₂-{(1*S*,3*S*)-Ac₅c^{OM}}]₂-OMe (**1e**); hexamer



(b) Boc-[(Leu)₂-{(1*S*,3*S*)-Ac₅c^{OM}}]₃-OMe (**2e**); nonamer



(c) H-[(Leu)₂-{(*S,S*)-Ac₅c^{dOM}}]₄-OMe (**6c**); dodecamer




Table S2. Intra- and intermolecular H-bond parameters for Boc-[L-Leu-L-Leu- $\{(1S,3S)\text{-Ac}_5\text{c}^{\text{OM}}\}]_2\text{-OMe } \mathbf{1e}$.

Peptide	Donor	Acceptor	Distance [Å]	Angle [°]	parameters
	D—H	A	D \cdots A	D—H \cdots A	Symmetry Operations
Mol. A (<i>P</i>)	N3a-H	O0a	3.01	157.3	x,y,z
	N4a-H	O1a	2.98	137.6	x,y,z
	N5a-H	O1a	3.01	158.6	x,y,z
	N6a-H	O2a	3.02	163.8	x,y,z
Mol. B (<i>P</i>)	N3b-H	O0b	3.04	155.5	x,y,z
	N4b-H	O1b	2.95	135.2	x,y,z
	N5b-H	O1b	2.95	157.3	x,y,z
	N6b-H	O2b	3.02	164.7	x,y,z
Mol. C (<i>P</i>)	N3c-H	O0c	3.04	153.8	x,y,z
	N4c-H	O1c	2.98	131.7	x,y,z
	N5c-H	O1c	3.12	161.4	x,y,z
	N6c-H	O2c	2.92	162.7	x,y,z
<i>P'</i>	N1a-H	O5a'	2.99	165.3	-y.x-y,1/3+z
	N2a-H	O4a'	2.99	167.3	-y.x-y,1/3+z
	N2a'-H	O4a	2.99	167.3	-x+y.-x,-1/3+z
	N1a'-H	O5a	2.99	165.3	-x+y.-x,-1/3+z
	N1b-H	O5b'	2.86	157.1	1-y.x-y,1/3+z
	N2b-H	O4b'	2.92	162.9	1-y.x-y,1/3+z
	N2b'-H	O4b	2.92	162.9	1-x+y.1-x,-1/3+z
	N1b'-H	O5b	2.86	157.1	1-x+y.1-x,-1/3+z
	N1c-H	O5c'	2.90	153.6	1-y.1+x-y,1/3+z
	N2c-H	O4c'	3.02	165.4	1-y.1+x-y,1/3+z
	N2c'-H	O4c	3.02	165.4	-x+y.1-x,-1/3+z
	N1c'-H	O5c	2.90	153.6	-x+y.1-x,-1/3+z

Table S3. Intra- and intermolecular H-bond parameters for Boc-[L-Leu-L-Leu- $\{(1S,3S)\text{-Ac}_5\text{c}^{\text{OM}}\}]_3$ -OMe **2e**.


Peptide	Donor D—H	Acceptor A	Distance [Å] D \cdots A	Angle [$^\circ$] D—H \cdots A	Symmetry Operations
Mol. A (<i>P</i>)	N4a-H	O0a	3.17	167.1	x,y,z
	N5a-H	O1a	2.80	167.8	x,y,z
	N6a-H	O2a	3.04	164.0	x,y,z
	N7a-H	O3a	3.07	149.4	x,y,z
	N8a-H	O4a	2.92	154.1	x,y,z
	N9a-H	O5a	2.98	159.4	x,y,z
Mol. B (<i>P</i>)	N4b-H	O1b	3.05	117.3	x,y,z
	N5b-H	O1b	3.09	161.0	x,y,z
	N6b-H	O2b	2.92	164.7	x,y,z
	N8b-H	O4b	2.99	156.6	x,y,z
	N9b-H	O5b	2.98	170.7	x,y,z
	N1a-H	O8a'	2.83	169.9	x,-1+y,z
	N1a'-H	O8a	2.83	169.9	x,-1+y,z
	Ow(a')-H	O7a	2.83	160.5	x,1+y,z
	Ow(b')-H	O6a	2.93	158.7	x,1+y,z
	Ow(b'')-H	OM6a	2.92	153.1	2-x,1/2+y,1/2-z
	N1b'-H	O7b	2.90	140.1	x,-1+y,z
	N1b-H	O7b'	2.90	140.1	x,1+y,z
	N3b-H	Ow(d')	2.95	154.9	x,1+y,z
	N3b'-H	Ow(d)	2.95	154.9	x,-1+y,z
	Ow(a)-H	O7a'	2.83	160.5	x,-1+y,z
	Ow(b)-H	O6a'	2.93	158.7	x,-1+y,z
	Ow(b)-H	OM6a'	2.92	153.1	2-x,-1/2+y,1/2-z

The distances of N7b \cdots O3b (3.41 Å) and N4b \cdots O0b (3.88 Å) are too long for intramolecular H-bonds. The distance of N4a \cdots O0a (3.17 Å) is a bit long for an intramolecular H-bond. W: water, OM: OMe group of cyclic amino acids.


Table S4. Intra-^{dOM} and intermolecular H-bond parameters for H-[L-Leu-L-Leu- $\{(S,S)$ -Ac₅c^{dOM} $\}]_4$ -OMe **6c**.

Peptide	Donor D—H	Acceptor A	Distance [Å] D···A	Angle [°] D—H···A	Symmetry Operations
(P)	N4-H	O1	2.92	119.6	x,y,z
	N5-H	O1	2.92	164.8	x,y,z
	N6-H	O2	2.90	170.1	x,y,z
	N7-H	O3	3.18	160.4	x,y,z
	N8-H	O4	2.86	166.5	x,y,z
	N9-H	O5	3.05	163.4	x,y,z
	N11-H	O7	2.90	145.2	x,y,z
	N12-H	O8	3.14	137.8	x,y,z
	N2'-H	O11	2.89	124.6	x,y,-1+z
	N2-H	O11'	2.89	124.6	x,y,1+z
	N2-H	O _{DMF}	3.06	91.0	x,y,z
	N3-H	O _{DMF}	2.81	172.9	x,y,z


The distance of N7 ··· O3 (3.18 Å) is a bit long for an intramolecular H-bond, and that of N10 ··· O6 (3.30 Å) is too long for an intramolecular H-bond. W: water, OM: OMe group of cyclic amino acids. The side chain of the Leu⁴ residue was disordered, and one DMF molecule existed, but was disordered at two positions.




9a















9d


































































































6a

